1,446 results on '"Fanin, Renato"'
Search Results
2. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
3. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT
4. Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
5. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT
6. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
7. Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
8. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide
9. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
10. JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response
11. Clinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey
12. Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study
13. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
14. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia
15. The burden of multiple myeloma: assessment on occurrence, outcomes and cost using a retrospective longitudinal study based on administrative claims database
16. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
17. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
18. Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
19. Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
20. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial
21. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
22. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO)
23. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
24. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group
25. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience
26. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell–Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia
27. Management of immune thrombocytopenia in elderly patients
28. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
29. The Role of Allogeneic Transplantation in Chronic Myeloid Leukemia in 2023: A Case-Based Concise Review
30. P1513: REDUCTION OF THE PROPHYLACTIC EFFECT OF TIXAGEVIMAB-CILGAVIMAB IN THE OMICRON ERA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND WITHOUT ANTIBODY RESPONSE FOLLOWING SARS-COV-2 VACCINATION.
31. PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
32. P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION
33. P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
34. PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
35. Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination
36. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy
37. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
38. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi
39. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation
40. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT
41. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
42. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission
43. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
44. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
45. Pulmonary actinomycosis by Actinomyces graevenitzii in two hematologic patients.
46. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients
47. Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation
48. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey
49. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
50. Supplementary Table S1 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.